• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Acute Spinal Cord Injury - Pipeline Review, Q4 2010 - Product Image

Acute Spinal Cord Injury - Pipeline Review, Q4 2010

  • Published: December 2010
  • 46 pages
  • Global Markets Direct

Acute Spinal Cord Injury - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Acute Spinal Cord Injury Pipeline Review, Q4 2010”, provides an overview of the Acute Spinal Cord Injury therapeutic pipeline. This report provides information on the therapeutic development for Acute Spinal Cord Injury , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury . “Acute Spinal Cord Injury -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Acute Spinal Cord Injury   .
- A review of the Acute Spinal Cord Injury    products under development by companies and universities/research institutes based on information derived from READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Spinal Cord Injury Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Spinal Cord Injury
Acute Spinal Cord Injury Therapeutics under Development by Companies
Acute Spinal Cord Injury Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Acute Spinal Cord Injury Therapeutics Development
NsGene A/S
Novartis AG
Alseres Pharmaceuticals, Inc.
Acorda Therapeutics, Inc.
Geron Corporation
Oxygen Biotherapeutics, Inc.
Proneuron Biotechnologies, Inc.
SYGNIS Pharma AG
Baylor College of Medicine
Spectrum Pharmaceuticals, Inc.
Noscira, S.A.
AnaMar Medical AB
AIM Therapeutics Inc.
SanBio, Inc.
KAI Pharmaceuticals Inc.
Universities/Institutes Involved in Acute Spinal Cord Injury Therapeutics Development
Acute Spinal Cord Injury Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
Cialis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Nitro L-arginine-methylester - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Propofol + Remifentanil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Spinal Cord Injury - Featured News
Dec 07, 2010: StemCells Receives Authorization To Conduct Neural Stem Cell Trial In Spinal Cord Injury
Oct 11, 2010: Geron Initiates Clinical Trial Of Human Embryonic Stem Cell-Based Therapy
Sep 20, 2010: Oxygen Biotherapeutics Amends CRADA With US Navy To Include Preclinical Studies Of Oxycyte For Spinal Cord Injury And Hemorrhagic Shock
Jul 30, 2010: Geron To Proceed With Human Clinical Trial Of GRNOPC1 In Patients With Acute Spinal Cord Injury
Jun 03, 2010: Study Shows Marked Neuroprotective Effects of Oxycyte Perfluorocarbon Emulsion in a Rat Model of Spinal Cord Injury
May 19, 2009: NsGene Granted European Patent Rights To Its Novel Neurotrophic Factor Meteorin For The Treatment Of Neurological Disorders
Sep 18, 2008: The European Commission Grants Orphan Drug Designation To Cethrin For The Treatment Of Traumatic Spinal Cord Injury (SCI)
Aug 25, 2008: Oxygen Biotherapeutics, Inc. to Meet With FDA to Discuss Proposed Phase II-b Oxycyte Clinical Trial
Apr 24, 2008: Amkor Pharma Completes All Clinical Activities For Its Phase I Study Of Neu2000For Treatment Of Acute Brain Injury
Apr 14, 2008: Oxygen Biotherapeutic Announces Filing of Protocol for Phase II-b Oxycyte Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos